Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Takeda Pharmaceutical Co Ltd | 10 |
| 2 | Bristol Myers Squibb Co | 4 |
| 3 | Vanderbilt University | 4 |
| 4 | Cumberland Pharmaceuticals Inc | 1 |
| 5 | Regeneron Pharmaceuticals Inc | 1 |
Where innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 41 |
| 2 | A61P | Therapeutic activity (drug indications) | 40 |
| 3 | Y02A | Climate change adaptation | 5 |
| 4 | C07D | Heterocyclic compounds | 1 |
| 5 | C12N | Microorganisms, enzymes | 1 |
| 6 | C12Q | Measuring/testing involving enzymes | 1 |
| 7 | C12Y | Enzyme nomenclature (EC numbers) | 1 |
| 8 | G01N | Investigating / analysing materials | 1 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents | 1995 | Bristol Myers Squibb Co | 62 |
| Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromboxane A2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation | 1994 | Bristol Myers Squibb Co | 40 |
| Methods of potentiating organic nitrates having vasodilating activity and formulations for the same | 2001 | 10 | |
| Use of a thromboxane A2 receptor antagonist for the manufacture of a medicament for the treatment of ulcerative gastrointestinal conditions | 1991 | Bristol Myers Squibb Co | 13 |
| Dual antagonist of PGD2/DPr2 and Thromboxane A2/TPr receptors and use for treatment of maladaptive immune response or thrombotic diathesis | 2023 | 1 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Hiroaki Shirahase | Kyoto University | 8 |
| 2 | Kenji Okumura | Nagoya University | 6 |
| 3 | Hachiro Usui | Kyoto University | 6 |
| 4 | Yukio Toki | Nagoya University | 5 |
| 5 | Motohatsu Fujiwara | Kyoto University | 5 |
| 6 | Noboru Toda | Shiga University of Medical Science | 5 |
| 7 | Kazuyoshi Kurahashi | Kyoto University | 5 |
| 8 | Hidekazu Hashimoto | Nagoya University | 5 |
| 9 | Alan H. Stephenson | Saint Louis University | 4 |
| 10 | A. Koda | Gifu Pharmaceutical University | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Linear type azo-containing polyurethane as drug-coating material for colon-specific delivery: its properties, degradation behavior, and utilization for drug formulation | 2000 | 110 | Drug Solubulity and Delivery Systems |
| Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548) | 1986 | 109 | Platelet Disorders and Treatments |
| Endothelium-dependent and -independent responses to vasodilators of isolated dog cerebral arteries. | 1988 | 54 | Traumatic Brain Injury and Neurovascular Disturbances |
| Synthesis and in vitro activity of stereoisomers of a novel thromboxane receptor antagonist, (.+-.)-(5Z)-7-[(3-endo-[(phenylsulfonyl)amino]bicyclo[2.2.1]hept-2-exo-yl]heptenoic acid | 1990 | 46 | Inflammatory mediators and NSAID effects |
| Native Lipoproteins Inhibit Platelet Activation Induced by Oxidized Lipoproteins | 1996 | 45 | Antioxidant Activity and Oxidative Stress |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of ONO-3708?
Which organizations hold the most patents for ONO-3708?
What was the patent activity for ONO-3708 in recent years?
What is the primary research focus indicated by the patent classifications for ONO-3708?
Which paper provides binding characterization data for ONO-3708 as a thromboxane receptor antagonist?